CJC-1295 NO DAC (Mod GRF 1-29) (5mg) Research Peptide: A Short‑Acting GHRH Analog for Pulsatile GH & IGF‑1 Studies

If your research investigates the dynamics of growth hormone (GH) secretion, the regulation of the hypothalamic‑pituitary‑somatotropic axis, or the physiological effects of pulsatile GH release, CJC-1295 NO DAC (Mod GRF 1-29) (5mg) research peptide offers a precisely defined and mechanistically valuable synthetic tool. CJC‑1295 NO DAC — also known as Modified GRF 1‑29 — is a short‑acting, tetrasubstituted 29‑amino‑acid analogue of growth hormone‑releasing hormone (GHRH). Unlike its DAC‑conjugated counterpart, which provides sustained, continuous GHRH receptor engagement, CJC‑1295 NO DAC has a half‑life of approximately 30 minutes and supports a pulsatile release pattern that closely replicates the natural, physiological secretion of growth hormone.

This short duration is not a limitation for pulsatile GH release models; rather, it is a deliberate design feature that supports research into the body’s natural, pulsatile GH secretion patterns. The absence of the Drug Affinity Complex (DAC) moiety means this peptide does not bind to serum albumin for extended periods. This makes CJC-1295 NO DAC (Mod GRF 1-29) (5mg) research peptide a valuable tool for laboratories investigating endocrine signalling, metabolic regulation, and the comparative pharmacology of short‑ versus long‑acting GHRH analogues.

At Chinese Grey Peptides, we supply high‑purity CJC-1295 NO DAC (Mod GRF 1-29) (5mg) research peptide to research institutions and wholesale buyers across the United Kingdom, France, Germany, Spain, Sweden, Italy, and the USA. Every batch is lyophilised, HPLC‑verified to >99% purity, and accompanied by a Certificate of Analysis (COA), ensuring your investigations into GH dynamics, IGF‑1 signalling, and metabolic research begin with uncompromising quality.

What Is CJC‑1295 NO DAC (Mod GRF 1‑29) and How Does It Work?

To fully appreciate the research potential of CJC‑1295 NO DAC (Mod GRF 1‑29) (5mg) research peptide, it is essential to understand its biochemical structure and the mechanism by which it achieves pulsatile GH stimulation.

The Tetrasubstituted 29‑Amino‑Acid GHRH Analog

CJC‑1295 NO DAC is a synthetic 29‑amino‑acid peptide derived from the first 29 amino acids of endogenous growth hormone‑releasing hormone (GHRH), the shortest fully functional fragment of the native hormone. The peptide features four specific amino acid substitutions that confer resistance to enzymatic degradation, particularly by dipeptidyl peptidase‑4 (DPP‑IV). These modifications include D‑Alanine at position 2, which is a key alteration that prevents rapid degradation by DPP‑IV. Its molecular formula is C₁₅₂H₂₅₂N₄₄O₄₂, with a molecular weight of approximately 3,367.97 g/mol and a CAS number of 446036‑97‑1.

The defining feature of CJC‑1295 NO DAC is the absence of the Drug Affinity Complex (DAC) moiety. Without DAC, the peptide cannot covalently bind to serum albumin, and therefore has a short half‑life of approximately 30 minutes. This short duration is not a limitation for pulsatile GH release models; rather, it is a deliberate design feature that supports research into the body’s natural, pulsatile GH secretion patterns.

Mechanism of Action: Pulsatile GHRH Receptor Activation

The biological activity of CJC‑1295 NO DAC (Mod GRF 1‑29) (5mg) research peptide is mediated through its short‑lived activation of the GHRH receptor:

• GHRH Receptor Binding: CJC‑1295 NO DAC binds to GHRH receptors (GHRH‑R) located on somatotroph cells in the anterior pituitary gland.

• cAMP/PKA Signalling Cascade: Receptor activation stimulates adenylyl cyclase to convert ATP into cyclic AMP (cAMP). The increase in intracellular cAMP activates Protein Kinase A (PKA), which phosphorylates downstream targets.

• Pulsatile GH Synthesis and Secretion: This signalling cascade culminates in the synthesis and secretion of growth hormone (GH) in a pulsatile manner that mimics the body’s natural rhythm. Peak GH elevation occurs at 30 to 60 minutes post‑administration.

• IGF‑1 Elevation: The released GH stimulates the liver to produce insulin‑like growth factor 1 (IGF‑1).

Research Note: NO DAC vs. DAC Distinction

The absence of the DAC moiety fundamentally distinguishes CJC‑1295 NO DAC from its DAC‑conjugated counterpart. CJC‑1295 NO DAC has a short half‑life of approximately 30 minutes and supports a pulsatile release pattern that mimics natural physiology. CJC‑1295 with DAC has a half‑life of 6‑8 days and produces a sustained, continuous GH bleed. For research models that aim to study the physiological effects of pulsatile GH release — rather than sustained elevation — the NO DAC variant is the preferred tool.

Key Research Applications for CJC-1295 NO DAC (Mod GRF 1-29) (5mg)

CJC‑1295 NO DAC (Mod GRF 1‑29) (5mg) research peptide is a versatile tool with applications spanning several domains of biomedical research.

1. Pulsatile GH & IGF‑1 Signalling Research

The defining feature of CJC‑1295 NO DAC—its short half‑life and pulsatile action—makes it a valuable tool for studying physiological GH secretion patterns. Research applications include:

• Pulsatile GH Dynamics: Investigating the amplitude, frequency, and physiological significance of pulsatile GH release

• IGF‑1 Elevation Studies: Studying the relationship between GH pulses and IGF‑1 production

• Comparative Pharmacokinetics: Comparing the effects of short‑acting (NO DAC) versus long‑acting (DAC) GHRH analogues on GH secretion patterns

• Sleep Architecture: Researching the impact of amplified GH pulses on slow‑wave sleep (SWS) and recovery cycles in animal models

2. Receptor Pharmacology & Signal Transduction Research

As a short‑acting GHRH analogue, CJC‑1295 NO DAC serves as a molecular probe for studying GHRH receptor pharmacology:

• Receptor Binding Studies: Characterising the binding affinity and kinetics of GHRH‑R engagement

• Signal Transduction: Dissecting the cAMP/PKA signalling cascade activated by transient GHRH receptor engagement

• Receptor Desensitisation: Investigating the potential for receptor down‑regulation following repeated, short‑lived activation

3. Synergistic Combination Studies

Research indicates that combining CJC‑1295 NO DAC with other GH secretagogues may result in synergistic interactions:

• GHRP‑2, GHRP‑6, and Ipamorelin Combinations: These peptides stimulate GH release through pathways distinct from GHRH, possibly involving ghrelin receptors

• Amplified GH Release: The GHRH and GHRP pathways synergize to produce GH pulses significantly larger than either agent alone

• Multiplied GH Release: It is frequently used in combination with GHRPs to study the synergistic “multiplier effect” on pituitary somatotrophs

4. Neuroendocrine & Endocrine Research

CJC‑1295 NO DAC is used to study the neuroendocrine regulation of the GH axis:

• Hypothalamic‑Pituitary Axis: Investigating the feedback mechanisms that regulate GH secretion, including somatostatin and IGF‑1 negative feedback loops

• Circadian GH Rhythm: Studying how pulsatile GHRH stimulation affects the natural circadian rhythm of GH secretion

• Pulse Amplitude Studies: Characterising how short‑acting GHRH analogues amplify the natural peaks of GH secretion when timed with endogenous somatostatin inhibition

Chemical & Physical Specifications for CJC-1295 NO DAC (Mod GRF 1-29) (5mg)

Accurate characterisation of CJC‑1295 NO DAC (Mod GRF 1‑29) (5mg) research peptide is essential for reproducible experimental design.

Note: The 5 mg mass refers to the weight of the peptide in its lyophilised form. CJC‑1295 NO DAC is typically supplied as a TFA or acetate salt, which enhances aqueous solubility. The peptide does not contain the Drug Affinity Complex (DAC) moiety, which is why it has a short half‑life and supports pulsatile GH release.

Reconstitution & Handling Protocol for CJC-1295 NO DAC (Mod GRF 1-29) (5mg)

Proper reconstitution of CJC‑1295 NO DAC (Mod GRF 1‑29) (5mg) research peptide is critical for maintaining its structural integrity and biological activity.

Step 1 – Preparation

• Bring the sealed CJC‑1295 NO DAC vial and your chosen diluent (sterile bacteriostatic water or sterile PBS, pH 5‑7) to room temperature. Condensation can degrade the lyophilised powder.

• Clean your work surface with 70% ethanol and lay out sterile syringes, alcohol wipes and a clean work mat.

Step 2 – Vial Sanitisation

• Wipe the rubber stopper of the CJC‑1295 NO DAC vial with a fresh 70% ethanol wipe. Allow the alcohol to evaporate completely before piercing.

Step 3 – Reconstitution

• Draw your desired volume of diluent into a sterile syringe. A common starting concentration for research applications is 5 mg per 0.5‑1 mL of diluent, yielding a 5‑10 mg/mL stock solution.

• Insert the needle and slowly inject the diluent against the inner glass wall. Do not spray directly onto the lyophilised powder.

• Gently swirl the vial until the solution is clear and fully dissolved. Do not shake vigorously, as shaking can cause denaturation.

Step 4 – Aliquoting & Storage

• Immediately after dissolution, aliquot the reconstituted CJC‑1295 NO DAC into single‑use sterile vials.

• Store aliquots at –20°C. Avoid repeated freeze‑thaw cycles, as peptides are susceptible to degradation.

• Once thawed, store at 2‑8°C and use within a short period.

Concentration Reference Table for CJC-1295 NO DAC (Mod GRF 1-29) (5mg)

Adjust diluent volume based on your experimental requirements. For cell culture applications, typical working concentrations may range from 0.1‑10 µM.

Storage & Stability Guidelines for CJC-1295 NO DAC (Mod GRF 1-29) (5mg)

Why Choose Chinese Grey Peptides for CJC-1295 NO DAC (Mod GRF 1-29) (5mg)?

As an authentic licensed peptide supplier based in the USA, we supply CJC‑1295 NO DAC (Mod GRF 1‑29) (5mg) research peptide and a wide range of research‑grade compounds under rigorous quality assurance protocols, fully aligned with Google’s E‑E‑A‑T standards (Experience, Expertise, Authoritativeness, Trustworthiness).

• Verified Purity: Independent HPLC analysis with purity guaranteed >99% for every batch

• Mass Spectrometry Verification: Confirms the presence of the four amino acid substitutions that define “Mod GRF”

• TFA Removal: Processed via acetate exchange to ensure high viability in sensitive cell culture applications

• Full Traceability: Batch‑specific Certificates of Analysis (COA) are available for every order

• Wholesale Supply: We serve research institutions, laboratories, and wholesale buyers across the UK, EU, and USA with flexible volume pricing and reliable logistics

• USA‑Based Regulatory Compliance: All products are supplied strictly as research‑grade chemicals for laboratory use only (RUO)

Researchers across the United States—including those at leading institutions—trust us for fast domestic delivery, transparent documentation and professional technical support.

FAQ: CJC-1295 NO DAC (Mod GRF 1-29) (5mg) Research Peptide

What is CJC-1295 NO DAC (Mod GRF 1-29) (5mg) research peptide?
CJC‑1295 NO DAC (also known as Modified GRF 1‑29) is a synthetic 29‑amino‑acid analogue of growth hormone‑releasing hormone (GHRH) that does not contain a Drug Affinity Complex (DAC) moiety. It has a short half‑life of approximately 30 minutes and supports a pulsatile release pattern that mimics the body’s natural GH secretion.

What is the sequence and molecular weight of CJC‑1295 NO DAC?
The sequence is Tyr‑D‑Ala‑Asp‑Ala‑Ile‑Phe‑Thr‑Gln‑Ser‑Tyr‑Arg‑Lys‑Val‑Leu‑Ala‑Gln‑Leu‑Ser‑Ala‑Arg‑Lys‑Leu‑Leu‑Gln‑Asp‑Ile‑Leu‑Ser‑Arg‑NH₂ with four amino acid substitutions that enhance stability. Its molecular weight is approximately 3,367.97 g/mol.

What are the primary research applications for CJC‑1295 NO DAC?
CJC‑1295 NO DAC is used in pulsatile GH and IGF‑1 signalling research, receptor pharmacology and signal transduction studies, synergistic combination studies with GHRPs (Ipamorelin, GHRP‑2, GHRP‑6), and neuroendocrine and endocrine research.

 What is the mechanism of action of CJC‑1295 NO DAC?
CJC‑1295 NO DAC binds to GHRH receptors on pituitary somatotrophs, activating a G‑protein signalling cascade that increases cAMP, activates PKA, and stimulates GH synthesis and secretion in a pulsatile manner that mimics natural physiology. Peak GH elevation occurs at 30 to 60 minutes post‑administration.

 How does CJC‑1295 NO DAC differ from CJC‑1295 with DAC?
CJC‑1295 NO DAC has a half‑life of 30 minutes and supports pulsatile GH release. CJC‑1295 with DAC has a half‑life of 6‑8 days and produces a sustained, continuous GH bleed. The NO DAC version more closely mimics natural GH pulses but requires daily or multiple daily injections.

What purity does your CJC‑1295 NO DAC (Mod GRF 1‑29) (5mg) meet?
Our CJC‑1295 NO DAC is tested to >99% purity by HPLC. A Certificate of Analysis (COA) is supplied with every order.

 How should I reconstitute CJC‑1295 NO DAC (Mod GRF 1‑29) (5mg)?
Reconstitute with sterile bacteriostatic water or sterile PBS (pH 5‑7). Allow the vial to reach room temperature, then slowly inject the diluent against the inner glass wall and swirl gently. Do not shake.

How should I store reconstituted CJC‑1295 NO DAC?
Reconstituted CJC‑1295 NO DAC should be stored at 2‑8°C for short‑term use. For longer storage, aliquot immediately into single‑use vials and store at –20°C for up to 3 months. Avoid repeated freeze‑thaw cycles.

Is CJC‑1295 NO DAC (Mod GRF 1‑29) research peptide legal to purchase in the USA?
Yes. CJC‑1295 NO DAC is a laboratory reagent sold for research use only (RUO). It is fully legal to purchase, possess, and use in the United States for legitimate in‑vitro or in‑vivo scientific research, provided it is not marketed with therapeutic claims. Note: CJC‑1295 is not approved for human use and is banned by the World Anti‑Doping Agency (WADA) for athletic use.

Does Chinese Grey Peptides ship internationally?
Yes. We ship across the UK, Europe (France, Germany, Spain, Sweden, Italy), and the USA from our US warehouse. Wholesale pricing is available for bulk orders.

CJC-1295 NO DAC (Mod GRF 1-29) (5mg)

1. Shop Page
2. Bulk Orders Page
3. Contact Page
4. Shipping & Return Page
5. Peptide Purity Page

• PubChem CJC-1295
• FDA CJC-1295 compounding-risk information
• FDA compounded-drug risk overview
• WADA Growth Hormone Releasing Factors Testing Guide
• Google Product Structured Data
• Rank Math WooCommerce Product Schema

CJC-1295 NO DAC (Mod GRF 1-29) (5mg)

Ships to USA, Canada, UK & Europe

Chinese Grey Peptides supports shipping to the USA, Canada, the United Kingdom, France, Germany, Spain, Sweden, Italy, and Europe where permitted.

Shipping support may include:

• Order processing updates
• Packaging support
• Tracking information where available
• Wholesale shipment planning
• Destination-based shipping review
• Customer support during transit

Shipping times may vary by order size, carrier, destination, customs process, product status, and local requirements.

Why Choose Chinese Grey Peptides?

Chinese Grey Peptides focuses on quality, support, and clear communication. We help buyers review product details before placing an order.

Customers choose us for:

• Professional peptide supplier support
• Small and wholesale order options
• Product documentation support
• HPLC testing information where available
• Mass Spectrum documentation where available
• International shipping support
• Responsive communication
• Clear order assistance before payment

We aim to make the buying process transparent, professional, and documentation-focused.

CJC-1295 NO DAC (Mod GRF 1-29) (5mg)

Important Compliance Notice

CJC-1295 NO DAC 5mg may be regulated differently depending on the country, product type, labeling, intended use, buyer type, and destination. Chinese Grey Peptides does not provide medical advice, dosing instructions, injection guidance, growth hormone claims, anti-aging claims, fat-loss claims, muscle-growth claims, recovery claims, athletic-performance claims, bodybuilding claims, disease claims, treatment claims, or personal-use recommendations.

Customers are responsible for understanding and following all local laws, import rules, prescription requirements, compounding rules, sport-governing rules, labeling rules, and permitted-use requirements before ordering.

CJC-1295 NO DAC (Mod GRF 1-29) (5mg)

From its design as a tetrasubstituted, short‑acting GHRH analogue to its well‑documented role in supporting pulsatile GH release and IGF‑1 signalling, CJC-1295 NO DAC (Mod GRF 1-29) (5mg) research peptide provides a precisely defined and pharmacologically valuable platform for advanced endocrinological and metabolic research. Its ability to support pulsatile GH release — rather than sustained elevation — makes it a valuable tool for laboratories investigating physiological GH dynamics, receptor pharmacology, and the comparative effects of short‑ versus long‑acting GHRH analogues. By choosing high‑purity, lab‑verified CJC-1295 NO DAC (Mod GRF 1-29) (5mg) research peptide from Chinese Grey Peptides, you ensure that your research is built on a foundation of quality, reproducibility, and scientific integrity.

Ready to advance your research with CJC-1295 NO DAC (Mod GRF 1-29) (5mg)? Browse our product catalogue, request a wholesale quote, or contact our support team today to discuss your laboratory’s specific needs. Place your order now and receive GMP‑grade CJC‑1295 NO DAC delivered directly to your facility in the USA, UK, or Europe.CJC-1295 NO DAC (Mod GRF 1-29) (5mg)

CJC-1295 NO DAC (Mod GRF 1-29) (5mg),CJC-1295 NO DAC (Mod GRF 1-29) (5mg),CJC-1295 NO DAC (Mod GRF 1-29) (5mg),CJC-1295 NO DAC (Mod GRF 1-29) (5mg),CJC-1295 NO DAC (Mod GRF 1-29) (5mg),CJC-1295 NO DAC (Mod GRF 1-29) (5mg)